Contract Research Organizations Services Market By Type (Discovery, CMC, Preclinical, Clinical Research, and Laboratory Services), By Therapeutic Area (Oncology, CNS, and Cardiovascular), By End User (Pharmaceuticals & Biotechnological Companies and Medical Device Companies) and By Region - Trends, Analysis and Forecast till 2034

The increased incidence of chronic illnesses has stimulated healthcare spending.

Chronic disease prevalence is on the rise, and this is becoming a key factor in contract research organizations' services. Market growth. Urbanization has increased processed food consumption, pollution, exposure to pathogens, and a general decline in public health. Consuming unhealthy, processed food and exercising insufficiently can hurt one's health and lead to chronic conditions such as diabetes, heart disease, obesity, high blood pressure, and gastrointestinal disorders. As a result, R&D spending in the biotech, pharmaceutical, and healthcare industries has increased globally.

For example, in the United States, 41.2% of all fatalities from cardiovascular disease (CVD) in 2020 were attributable to coronary heart disease (CHD). In 2020, cardiovascular disease (CVD) accounted for 928,741 deaths in the US, making it the leading cause of death. There were estimated to be 1,958,310 new cases of cancer in the USA alone in 2023. To address the growing need for healthcare intervention, this constant rise is forcing companies that specialize in contract research to outsource the creation of new drugs.

An increase in clinical trial volume has led to a rise in outsourcing to contract research organizations.

The number of clinical trials being undertaken globally has significantly increased as a result of the rise in chronic disease cases, the growing need for therapeutic innovation, and the production of better medications, as well as the stricter quality rules following the pandemic. Due to the rising necessity to outsource many production-related tasks to contract research organizations, the global market for services provided by these organizations has grown exponentially in recent years.

The Pharmaceutical Intelligence Centre at Global Data recently released information showing that 22,338 clinical studies, comprising 36% of Phase II trials, were initiated in 2023 alone. Most of these trials were carried out in the areas of oncology and the central nervous system. The number of medications being developed globally is expected to continue rising.